Discover Opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Sep 30, 2024 to Sep 30, 2024
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| Office of Acquisition Managementt Policy | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL | Sep 30, 2024 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Premium
Clean & enrich your CRM automatically
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE
Effective Date
Apr 19, 2016
Expires
Effective: Apr 19, 2016
IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE
ActiveVENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.
Effective Date
Sep 15, 2023
Expires
Effective: Sep 15, 2023
VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.
ActiveTHE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE FOLLOWING DEVELOPMENT ESSENTIALS: CMC DEVELOPMENT, PRE-CLINICAL AND CLINICAL STUDIES, DEVICE DEVELOPMENT ACTIVITIES, HUMAN FACTORS TESTING, MARKET VIABILITY ASSESSMENTS ALONG WITH ALL ASSOCIATED REGULA
Effective Date
Sep 29, 2025
Expires
Effective: Sep 29, 2025
THE SCOPE OF WORK FOR THIS CONTRACT INCLUDES THE FOLLOWING DEVELOPMENT ESSENTIALS: CMC DEVELOPMENT, PRE-CLINICAL AND CLINICAL STUDIES, DEVICE DEVELOPMENT ACTIVITIES, HUMAN FACTORS TESTING, MARKET VIABILITY ASSESSMENTS ALONG WITH ALL ASSOCIATED REGULA
ActiveIGF::OT::IGF - BASE PERIOD AWARD TO INBIOS INTERNATIONAL, INC. FOR POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX
Effective Date
Sep 26, 2017
Expires
Effective: Sep 26, 2017
IGF::OT::IGF - BASE PERIOD AWARD TO INBIOS INTERNATIONAL, INC. FOR POINT-OF-CARE IMMUNOASSAY FOR DIAGNOSIS OF INHALATIONAL ANTHRAX
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Get complete source documentation & analysis